GlassScriptPhysician profile
Marc Kenneth Lay
NPI 1497060362
$4,089.43
in general payments reported to CMS, 2019-2025
27 companies · $1,103 in 2025
The $1,103 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $375 · 2021: $722 · 2022: $509 · 2023: $462 · 2024: $562 · 2025: $1,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,021 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,020.88 |
| Education | $105.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $813.18 | 2019-2025 | Cequa |
| Alcon Vision LLC | $502.33 | 2021-2025 | Clareon Panoptix Pro, Rocklatan, Tryptyr |
| Mallinckrodt Hospital Products INC. | $441.07 | 2021-2025 | Acthar |
| Oyster Point Pharma, INC. | $397.91 | 2022-2025 | Tyrvaya |
| Allergan, INC. | $329.57 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $320.88 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Dompe US, INC. | $186.04 | 2021-2025 | Oxervate |
| Amgen INC. | $180.41 | 2025 | Tepezza |
| Lombart Brothers, INC. | $142.22 | 2021-2023 | Opd-III |
| Novartis Pharmaceuticals Corporation | $102.48 | 2019-2021 | |
| Harrow Eye, LLC | $95.26 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $84.03 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $79.91 | 2019-2021 | |
| Abbvie INC. | $59.83 | 2024-2025 | |
| Biotissue Holdings INC. | $59.80 | 2020-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $44.00 | 2023 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $37.54 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $30.61 | 2024 | Tecnis Iol |
| Rxsight INC | $26.93 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Astellas Pharma US INC | $26.55 | 2024 | Izervay |
| Sight Sciences, INC. | $21.40 | 2023 | Tearcare System |
| Iridex Corporation | $19.95 | 2021 | |
| Rayner Intraocular Lenses Limited | $19.86 | 2025 | Rayner Cataract Set 1, Rayone Emv, Rayone Spheric |
| Shire North American Group INC | $19.52 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec USA, INC. | $16.43 | 2025 | Cirrus Hd-Oct |
| Coopervision INC. | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Lay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.